免疫检查点抑制剂在三阴性乳腺癌治疗中的新作用。
The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
机构信息
University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab 140413, India.
State Key Laboratory of ASIC and System, SIST, Fudan University, 200433 Shanghai, China.
出版信息
Drug Discov Today. 2021 Jul;26(7):1721-1727. doi: 10.1016/j.drudis.2021.03.011. Epub 2021 Mar 18.
Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.
三阴性乳腺癌（TNBC）是一组异质性的乳腺癌，缺乏雌激素受体、孕激素受体和表皮生长因子受体 2 的表达。在过去的十年中，免疫检查点抑制剂（ICIs）彻底改变了癌症免疫治疗领域。现在，涉及使用根治性 ICI 治疗 TNBC 的试验正在积累早期结果，包括包含 ICI 技术的联合治疗。在这篇综述中，我们提供了基于免疫疗法治疗进展的广泛概述，并讨论了它们在 TNBC 中的未来应用机会。
Zotero 插件